가족성 지질단백 지질분해효소 결핍증 시장 - 인사이트, 역학, 시장 예측(2034년)

Key Highlights:

• Familial lipoprotein lipase (LPL) deficiency, also known as Type I hypolipoproteinemia, is a rare genetic disorder caused by a lack of the LPL enzyme, leading to impaired fat digestion, chylomicron buildup in the blood (chylomicronemia), and severely elevated triglyceride levels. It is the most common form of familial chylomicronemia syndrome (FCS).
• The Familial Lipoprotein Lipase Deficiency market is expected to grow steadily from 2025 to 2034, driven by rising awareness of rare lipid disorders, advancements in genetic diagnostics, and the development of targeted therapies such as antisense oligonucleotides. Continued innovation in precision medicine and a strengthening clinical research pipeline are anticipated to support the market's ongoing expansion.
• In 2012, the European Commission granted marketing authorization for alipogene tiparvovec (GLYBERA), a gene therapy developed by UniQure, for the treatment of individuals with LPL deficiency. GLYBERA became the first gene therapy approved in the Western world but was never approved in the United States. Due to limited patient demand, UniQure withdrew GLYBERA from the market in 2017.
• TRYNGOLZA (olezarsen), developed by Ionis Pharmaceuticals, represents a major advancement as the first FDA-approved antisense therapy for FCS (type 1 Hyperlipoproteinemia). Its predecessor, WAYLIVRA (volanesorsen), received only conditional approval in Europe, highlighting both the evolving regulatory environment and the growing promise of RNA-based therapies in treating rare lipid disorders.
• Plozasiran, Arrowhead's investigational RNAi therapy targeting APOC3, shows strong promise for FCS treatment, with FDA review underway following positive Phase III PALISADE results-highlighting the growing impact of RNAi in rare lipid disorders.
• Market growth in Familial Lipoprotein Lipase Deficiency is driven by emerging genetic therapies and innovative approaches targeting the underlying metabolic defect. While strict dietary fat restriction remains standard, issues like poor adherence, recurrent pancreatitis, and limited pharmacologic options highlight the need for more effective treatments. Antisense oligonucleotides offer promise by reducing triglyceride levels and improving long-term outcomes and quality of life.

DelveInsight's comprehensive report titled "Familial Lipoprotein Lipase Deficiency- Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Familial Lipoprotein Lipase Deficiency. The report presents historical and projected epidemiological data covering total prevalent cases of Familial Lipoprotein Lipase Deficiency, total diagnosed prevalent cases of Familial Lipoprotein Lipase Deficiency, gender-specific cases of Familial Lipoprotein Lipase Deficiency, age-specific cases of Familial Lipoprotein Lipase Deficiency, and treated cases of Familial Lipoprotein Lipase Deficiency. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Familial Lipoprotein Lipase Deficiency. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Familial Lipoprotein Lipase Deficiency Overview

Familial lipoprotein lipase (LPL) deficiency is a rare inherited metabolic disorder caused by a deficiency of the LPL enzyme, which is essential for breaking down certain fats in the body. Without this enzyme, fatty particles called chylomicrons build up in the bloodstream (chylomicronemia), leading to severely elevated triglyceride levels. This fat accumulation disrupts normal metabolism and contributes to various clinical complications.

Individuals with LPL deficiency may experience recurrent abdominal pain, episodes of pancreatitis, enlargement of the liver and spleen (hepatosplenomegaly), and skin eruptions called eruptive xanthomas. The condition is most often linked to mutations in the LPL gene and follows an autosomal recessive inheritance pattern. However, recent studies have identified mutations in other genes that can produce a clinical presentation resembling LPL deficiency.

Familial Lipoprotein Lipase Deficiency Diagnosis and Treatment Algorithm

A diagnosis of familial LPL deficiency is typically based on the presence of characteristic symptoms, along with a comprehensive patient history and clinical examination. Healthcare providers may also use specific laboratory tests to support the diagnosis, particularly blood tests that assess fat metabolism and enzyme activity.

One key diagnostic approach involves measuring lipoprotein lipase activity in the blood after administering heparin, which helps release the enzyme into the plasma. A significant reduction in enzyme activity may indicate LPL deficiency. Definitive diagnosis can be achieved through molecular genetic testing to identify mutations in the LPL gene, which is available through specialized clinical and research laboratories.

Treatment for familial LPL deficiency primarily involves strict dietary fat restriction to reduce chylomicronemia and high triglyceride levels, which helps prevent symptoms like abdominal pain and pancreatitis. While some patients adapt by avoiding fatty foods on their own, clinical guidelines often recommend limiting fat intake to no more than 20 grams per day or 15% of daily calories. Unfortunately, standard lipid-lowering medications are ineffective in this condition, and substances that raise triglyceride levels-such as alcohol, oral contraceptives, diuretics, beta-blockers, isotretinoin, and Zoloft-should be avoided.

Medium-chain fatty acids, which are directly absorbed into the liver through the portal vein, are safe for cooking and are often included in the diet for managing LPL deficiency. Fish oil supplements, however, are not effective and should be avoided. As triglyceride levels normalize, enlarged organs like the liver or spleen typically return to normal size within a week, while eruptive xanthomas often resolve within weeks to months. Persistent or recurring xanthomas may signal inadequate dietary control or treatment adherence.

Familial Lipoprotein Lipase Deficiency Epidemiology

The epidemiology section of the Familial Lipoprotein Lipase Deficiency market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Familial Lipoprotein Lipase Deficiency. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

As per National Organization for Rare Disease (NORD), Familial LPL deficiency affects males and females equally and is estimated to occur in approximately 1 in 250,000 individuals in the general population.

According to secondary research, Familial LPL deficiency has an estimated prevalence of around 1 in 1,000,000 in the general population. Most cases are diagnosed during childhood, often before the age of 10, with about 25% identified within the first year of life. However, symptoms can sometimes appear later, and in some cases, females may first present during pregnancy.

The epidemiology of Familial Lipoprotein Lipase Deficiency is expected to change during the forecast period (2025-2034).

Familial Lipoprotein Lipase Deficiency Market Outlook

The Familial Lipoprotein Lipase Deficiency therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Familial Lipoprotein Lipase Deficiency market in the 7MM is expected to change significantly during the forecast period 2025-2034.

Familial Lipoprotein Lipase Deficiency Drug Chapters

Marketed Familial Lipoprotein Lipase Deficiency Drugs

TRYNGOLZA (olezarsen): Ionis Pharmaceuticals

TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the US for familial chylomicronemia syndrome, a potentially life-threatening disease. TRYNGOLZA had received Fast Track, Orphan Drug, and Breakthrough Therapy designations for the treatment of familial chylomicronemia syndrome (Familial lipoprotein lipase deficiency/Type I hypolipoproteinemia).

In December 2024, Ionis Pharmaceuticals announced that the US FDA has approved TRYNGOLZA (olezarsen) as a dietary adjunct for lowering triglyceride levels in adults with familial chylomicronemia syndrome.

WAYLIVRA (volanesorsen): Ionis Pharmaceuticals

WAYLIVRA, developed with Ionis' antisense technology, uses volanesorsen to target and reduce ApoC-III production, helping to lower triglyceride levels, improve metabolic balance, and reduce the risk of fat buildup and pancreatitis. WAYLIVRA is a medicine used to treat familial chylomicronaemia syndrome (Familial lipoprotein lipase deficiency/Type I hypolipoproteinemia).

In May 2019, Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, announced that WAYLIVRA has been granted conditional marketing authorization by the European Commission. It is approved as a dietary adjunct for adults with genetically confirmed FCS who are at high risk of pancreatitis and have not responded adequately to diet and triglyceride-lowering treatments.

Emerging Familial Lipoprotein Lipase Deficiency Drugs

The Familial Lipoprotein Lipase Deficiency market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as Plozasiran, by Arrowhead Pharmaceuticals among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.

Plozasiran: Arrowhead Pharmaceuticals

Plozasiran (formerly ARO-APOC3) is a first-in-class investigational RNAi therapy designed to lower apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism. By reducing APOC3, plozasiran enhances the breakdown of triglyceride-rich lipoproteins and improves lipid clearance. Clinical studies have shown it significantly reduces triglycerides and atherogenic lipoproteins in patients with familial chylomicronemia syndrome (Familial lipoprotein lipase deficiency/Type I hypolipoproteinemia).

In January 2025, Arrowhead Pharmaceuticals announced that the US FDA has accepted its New Drug Application for plozasiran as a treatment for familial chylomicronemia syndrome (FCS), based on favorable outcomes from the Phase III PALISADE trial.

Familial Lipoprotein Lipase Deficiency Market Segmentation

DelveInsight's 'Familial Lipoprotein Lipase Deficiency- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future Familial Lipoprotein Lipase Deficiency market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Familial Lipoprotein Lipase Deficiency Market Size by Countries

The Familial Lipoprotein Lipase Deficiency market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) Familial Lipoprotein Lipase Deficiency market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Familial Lipoprotein Lipase Deficiency Drugs Uptake

This section focuses on the sales uptake of potential Familial Lipoprotein Lipase Deficiency drugs that have recently been launched or are anticipated to be launched in the Familial Lipoprotein Lipase Deficiency market between 2020 and 2034. It estimates the market penetration of Familial Lipoprotein Lipase Deficiency drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Familial Lipoprotein Lipase Deficiency market.

The emerging Familial Lipoprotein Lipase Deficiency therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Familial Lipoprotein Lipase Deficiency market.

Familial Lipoprotein Lipase Deficiency Market Access and Reimbursement

DelveInsight's 'Familial Lipoprotein Lipase Deficiency- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of Familial Lipoprotein Lipase Deficiency.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Familial Lipoprotein Lipase Deficiency market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the Familial Lipoprotein Lipase Deficiency domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Familial Lipoprotein Lipase Deficiency market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Familial Lipoprotein Lipase Deficiency unmet needs.

Familial Lipoprotein Lipase Deficiency: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as UT Southwestern Medical Center, US, University Hospital Marburg, Germany, University of Barcelona, Spain, Universite Paris-Saclay, France, University of Manchester, UK, and Chiba University, Japan, among others.

"LPL deficiency typically manifests through symptoms linked to elevated lipid levels, with abdominal pain being the most common. This pain, often caused by acute pancreatitis, can vary from mild to severe and may mimic a surgical emergency. Repeated bouts of acute pancreatitis can eventually lead to chronic pancreatitis."

"Familial lipoprotein lipase (LPL) deficiency commonly appears in childhood, marked by recurring abdominal pain, repeated episodes of acute pancreatitis, skin eruptions known as eruptive xanthomas, and enlargement of the liver and spleen. The condition affects both males and females equally. While symptoms typically emerge early in life, some individuals may not present until later, including during pregnancy."

"Patients with LPL deficiency often experience loss of appetite, nausea, and vomiting. Enlargement of the liver and spleen (hepatosplenomegaly) is a result of extremely high triglyceride levels in the blood. Chylomicrons accumulate in the bloodstream and are absorbed by macrophages, which then migrate to the liver and spleen. The buildup of fat-laden cells in these organs leads to their swelling."

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Familial Lipoprotein Lipase Deficiency Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Familial Lipoprotein Lipase Deficiency Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Familial Lipoprotein Lipase Deficiency. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Familial Lipoprotein Lipase Deficiency therapies.

Familial Lipoprotein Lipase Deficiency Report Insights

• Familial Lipoprotein Lipase Deficiency Patient Population
• Therapeutic Approaches
• Familial Lipoprotein Lipase Deficiency Pipeline Analysis
• Familial Lipoprotein Lipase Deficiency Market Size and Trends
• Familial Lipoprotein Lipase Deficiency Market Opportunities
• Impact of Upcoming Therapies

Familial Lipoprotein Lipase Deficiency Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Familial Lipoprotein Lipase Deficiency Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Familial Lipoprotein Lipase Deficiency Market
• Familial Lipoprotein Lipase Deficiency Drugs Uptake

Familial Lipoprotein Lipase Deficiency Report Assessment

• Familial Lipoprotein Lipase Deficiency Current Treatment Practices
• Unmet Needs
• Familial Lipoprotein Lipase Deficiency Pipeline Product Profiles
• Familial Lipoprotein Lipase Deficiency Market Attractiveness

Key Questions:

• How common is Familial Lipoprotein Lipase Deficiency?
• What are the key findings of Familial Lipoprotein Lipase Deficiency epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for Familial Lipoprotein Lipase Deficiency?
• What are the disease risk, burden, and unmet needs of Familial Lipoprotein Lipase Deficiency?
• At what CAGR is the Familial Lipoprotein Lipase Deficiency market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the Familial Lipoprotein Lipase Deficiency market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Familial Lipoprotein Lipase Deficiency in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of Familial Lipoprotein Lipase Deficiency?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Familial Lipoprotein Lipase Deficiency Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for Familial Lipoprotein Lipase Deficiency?

The primary goals in managing Familial LPL Deficiency are to reduce plasma triglyceride levels, prevent episodes of acute pancreatitis, and alleviate related symptoms such as abdominal pain and nausea. Treatment focuses on minimizing chylomicron accumulation through strict dietary fat restriction, thereby improving metabolic stability and reducing the risk of complications. Long-term management also aims to improve quality of life, prevent organ damage (such as hepatosplenomegaly), and reduce reliance on emergency interventions.

2. What are the challenges in managing Familial Lipoprotein Lipase Deficiency?

Managing Familial Lipoprotein Lipase Deficiency presents several challenges due to its early onset, lifelong nature, and lack of curative treatments. Strict dietary fat restriction is difficult to maintain, especially in children and during life stages like pregnancy. The condition's rarity limits physician familiarity and access to specialized care. Additionally, there are limited effective pharmacologic options, and newer therapies such as gene therapy or antisense oligonucleotides remain costly and not widely available. These factors contribute to inconsistent disease control and increased risk of complications like recurrent pancreatitis.

3. What are the key factors driving the growth of the Familial Lipoprotein Lipase Deficiency market?

Key drivers of the Familial Lipoprotein Lipase Deficiency market include improved disease recognition, expanded genetic screening, and advances in lipid-lowering and RNA-based therapies. Regulatory incentives and rising awareness of severe complications like acute pancreatitis are supporting earlier diagnosis, lifelong management, and market growth.

4. How will the Familial Lipoprotein Lipase Deficiency Market and Epidemiology Forecast Report benefit the clients?

The report will provide comprehensive insights into the current Familial Lipoprotein Lipase Deficiency market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution by Therapies in 2024
• 3.2. Market Share (%) Distribution by Therapies in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
• 8.3. Total Prevalent Cases of Familial Lipoprotein Lipase Deficiency in the 7MM
• 8.4. Total Diagnosed Prevalent Cases of Familial Lipoprotein Lipase Deficiency in the 7MM
• 8.5. The US
  • 8.5.1. Total Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.5.2. Total Diagnosed Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.5.3. Gender-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.5.4. Age-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.5.5. Treated Cases of Familial Lipoprotein Lipase Deficiency
• 8.6. EU4 and the UK
  • 8.6.1. Total Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.6.2. Total Diagnosed Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.6.3. Gender-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.6.4. Age-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.6.5. Treated Cases of Familial Lipoprotein Lipase Deficiency
• 8.7. Japan
  • 8.7.1. Total Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.7.2. Total Diagnosed Prevalent Cases of Familial Lipoprotein Lipase Deficiency
  • 8.7.3. Gender-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.7.4. Age-specific Cases of Familial Lipoprotein Lipase Deficiency
  • 8.7.5. Treated Cases of Familial Lipoprotein Lipase Deficiency

9. Patient Journey

10. Marketed Therapies

• 10.1. Key Cross Competition
• 10.2. TRYNGOLZA (olezarsen): Ionis Pharmaceuticals
  • 10.2.1. Drug Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Development Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. WAYLIVRA (volanesorsen): Ionis Pharmaceuticals
  • 10.3.1. Drug Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Development Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Plozasiran: Arrowhead Pharmaceuticals
  • 11.2.1. Drug Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views

12. Familial Lipoprotein Lipase Deficiency: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of Familial Lipoprotein Lipase Deficiency in the 7MM
• 12.6. Market Size of Familial Lipoprotein Lipase Deficiency by Therapies in the 7MM
• 12.7. The US Market Size
  • 12.7.1. Total Market Size of Familial Lipoprotein Lipase Deficiency
  • 12.7.2. Market Size of Familial Lipoprotein Lipase Deficiency by Therapies
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Total Market Size of Familial Lipoprotein Lipase Deficiency
  • 12.8.2. Market Size of Familial Lipoprotein Lipase Deficiency by Therapies

12.9.. Japan Market Size

• 12.9.1. Total Market Size of Familial Lipoprotein Lipase Deficiency
• 12.9.2. Market Size of Familial Lipoprotein Lipase Deficiency by Therapies

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Familial Lipoprotein Lipase Deficiency Market Access and Reimbursement

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Abbreviations and Acronyms
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight